MEDADVISOR has achieved record 1H results and is on track for EBITDA growth in FY24, with revenue growing to $75.5 million, representing a 17.8% increase on the previous corresponding period.
Gross profit rose by 13.3% to $43.5 million, with gross margin declining by 2.4 percentage points to 57.6%, primarily due to a higher share in the lower margin traditional health communications campaigns in the United States.
EBITDA improved by 20.9% to $10.4 million, assisted by further cost management and scale benefits.
Gross cash position improved by $8.3 million to $22.5 million.
"In Australia, we are realising the full benefit of the GuildLink integration, subscription price increases and the Qld pilot contract," said CEO Rick Ratliff.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Feb 24
